SAGE - Sage Therapeutics, Inc.

7.77
-0.020   -0.257%

Share volume: 565,041
Last Updated: 04-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$7.79
-0.02
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 25%
Dept financing 30%
Liquidity 50%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.26%
1 Month
-2.26%
3 Months
6.00%
6 Months
-8.37%
1 Year
-45.20%
2 Year
-84.03%
Key data
Stock price
$7.77
P/E Ratio 
0.00
DAY RANGE
$7.69 - $7.86
EPS 
-$9.88
52 WEEK RANGE
$4.62 - $14.56
52 WEEK CHANGE
-$44.26
MARKET CAP 
332.171 M
YIELD 
N/A
SHARES OUTSTANDING 
61.050 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
2.59
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$862,416
AVERAGE 30 VOLUME 
$1,200,447
Company detail
CEO: Barry E. Greene
Region: US
Website: sagerx.com
Employees: 690
IPO year: 2012
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sage Therapeutics, Inc. develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor.

Recent news
loading